Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition

Figure 6

Impact of salirasib on ras expression and activation. A. Representative Western blots of ras after one and two days of treatment. B. Western blot of the independent experiments were quantified by densitometry and then normalized to their respective β-actin (n = 6 per group) Data are finally expressed as relative change compared to the control (DMSO) group arbitrarily set at 1. C. Quantification of H- and K-Ras mRNA expression by quantitative PCR after one day of treatment with salirasib (n = 6 per group). Data of the independent experiments were first normalized to RPL19 (internal standard) and then expressed as relative change versus control (DMSO) set arbitrarily at 1 (dotted line) and are presented as mean ± SEM. * P < 0.05, ** P < 0.01 and *** P < 0.001 in treated groups versus control group. D. Representative result of ras pull-down assays performed in 2 independent experiments in HepG2 cells stimulated with either EGF or IGF2 and treated with DMSO or 150 μM salirasib for 2 hours prior to stimulation.

Back to article page